Table 2 Group characteristics based on target levels for low-molecular-weight protein removal according to complications
From: Glycated hemoglobin and glycated albumin in patients with diabetes undergoing hemodiafiltration
Group A Non-protein-leaking OHDF | Group B Protein-leaking OHDF | Group C Highly efficient protein-leaking OHDF | p value | |
|---|---|---|---|---|
Classification of albumin leakage | ≤ 2.0 g | 2.1 g ≥, < 6.0 | 6.0 g ≥ | – |
Albumin leakage (g) | 0.85 ± 0.60 | 3.45 ± 1.08 | 7.64 ± 1.36 | – |
Number of patients (M/F) | 20 (15/5) | 14 (12/2) | 7(7/0) | – |
Age (years) | 75.0 ± 7.7 | 61.1 ± 8.8 | 57.6 ± 7.0 | < 0.0001 |
Dialysis history (months) | 67.7 ± 35.5 | 71.4 ± 52.0 | 96.0 ± 67.4 | 0.7176 |
Dialysis time (h) | 4.0 ± 0.3 | 3.9 ± 0.3 | 4.1 ± 0.2 | 0.7720 |
Blood flow rate (mL/min) | 221.1 ± 25.4 | 262.9 ± 21.6 | 257.1 ± 18.9 | 0.0011 |
Dialysate flow rate (mL/min) | 600 | 600 | 600 | – |
Replacement amount volume (L) | 59.5 ± 14.9 | 58.4 ± 10.1 | 65.7 ± 9.6 | 0.4695 |
Dry weight (kg) | 53.7 ± 9.3 | 70.4 ± 13.9 | 76.3 ± 10.9 | < 0.0001 |
Albumin (g/dL) | 3.3 ± 0.4 | 3.5 ± 0.3 | 3.3 ± 0.2 | 0.2272 |
UN (mg/dL) | 60.5 ± 17.2 | 57.2 ± 11.0 | 59.0 ± 14.5 | 0.7829 |
Hb (g/dL) | 10.2 ± 0.7 | 10.8 ± 1.6 | 10.7 ± 0.8 | 0.2394 |
Ht (%) | 30.4 ± 2.4 | 32.7 ± 4.3 | 32.2 ± 2.6 | 0.0799 |
Pre-dialysis blood glucose (mg/dL) | 131.1 ± 37.8 | 119.7 ± 48.6 | 133.8 ± 35.7 | 0.5783 |
HbA1c (%) | 6.0 ± 0.9 | 6.4 ± 0.9 | 6.3 ± 0.9 | 0.3197 |
GA (%) | 19.5 ± 2.6 | 18.4 ± 3.7 | 17.5 ± 4.5 | 0.2172 |
Fe (μg/dL) | 45.9 ± 27.6 | 59.7 ± 28.2 | 74.0 ± 53.2 | 0.3077 |
TIBC (μg/dL) | 211.3 ± 55.5 | 244.6 ± 49.8 | 243.7 ± 66.2 | 0.2961 |
TSAT (%) | 22.2 ± 12.5 | 24.8 ± 11.5 | 35.5 ± 30.3 | 0.6347 |
Ferritin (ng/dL) | 201.3 ± 183.4 | 206.2 ± 283.8 | 225.4 ± 206.6 | 0.9274 |
ESAs | ||||
Darbepoetin alfa (μg/week) (number) | 21.3 ± 23.8 (11) | 20.4 ± 5.9 (3) | 3.8 ± 3.5 (2) | – |
Epoetin beta (U/week) (number) | 2437.5 (1) | 3937.5 (1) | – | – |
Epoetin beta pegol (μg/week) (number) | 23.8 ± 12.0 (5) | 18.8 ± 4.4 (5) | 37.5 (1) | – |
ERI (each ESA dose/kg/g/dL/week) | ||||
Darbepoetin alfa | 0.012 ± 0.011 | 0.008 ± 0.003 | 0.002 ± 0.001 | – |
Epoetin beta | 4.2 | 6.3 | – | – |
Epoetin beta pegol | 0.049 ± 0.025 | 0.030 ± 0.008 | 0.043 | – |
Iron (intravenous administration) (mg/week) | ||||
Saccharated ferric oxide (number) | 65.0 ± 59.2 (4) | 50.0 ± 42.4 (2) | – | – |
Iron-based phosphate binder (oral administration) (mg/week) | ||||
Sucroferric oxyhydroxide (number) | 7000.0 ± 3031.1 (3) | 12250.0 ± 8019.5 (3) | 615.0 ± 1237.4 (2) | – |
Ferric citrate hydrate (number) | 10500.0 (2) | 22750 ± 6062.3 (3) | 15750 (2) | – |